title: Rivastigmine for Alzheimer's disease.
abstract: Alzheimer's disease is the most common form of neurodegenerative dementia and poses considerable health challenges to both patients and their families. Rivastigmine is a powerful slow-reversible, noncompetitive carbamate cholinesterase inhibitor that is approved for the treatment of mild-to-moderate Alzheimer's disease. Randomized, double-blind, placebo-controlled trials of up to 6 months duration have shown beneficial effects of rivastigmine compared with placebo in measures of cognition and global functioning. Less rigorous but growing data suggest that the beneficial effects may endure for up to 5 years, extend to more advanced stages of Alzheimer's disease and may occur in noncognitive domains, such as activities of daily living and the behavioral symptoms of Alzheimer's disease. Evidence from controlled studies also supports the use of rivastigmine for cognitive and behavioral symptoms in Alzheimer's disease associated with vascular risk factors, dementia with Lewy bodies and Parkinson's disease dementia. Early and continued treatment of Alzheimer's disease with rivastigmine maximizes the observed beneficial effects. The most prominent adverse effect of rivastigmine is centrally mediated cholinergic gastrointestinal events, which can be minimized by slower dose-escalation intervals and administration with a full meal. Therapeutic dosing is 6-12 mg/day given twice daily, with higher doses having the potential for greater benefits.
authors.affiliation: Alzheimer's Center of Excellence, Saint Louis University School of Medicine, 3211 E Northshore Boulavard, #157, Appleton, WI 54915, USA. abhilash.desai@thedacare.org
authors.forename: Abhilash K
authors.initials: AK
authors.lastname: Desai
authors.forename: George T
authors.initials: GT
authors.lastname: Grossberg
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000503:physiopathology / Q000523:psychology / Q000534:rehabilitation; D000818:Animals; D003072:Cognition Disorders / Q000188:drug therapy / Q000209:etiology; D003704:Dementia / Q000503:physiopathology / Q000523:psychology / Q000628:therapy; D005104:Expert Testimony; D006801:Humans; D015201:Meta-Analysis as Topic; D008954:Models, Biological; D018696:Neuroprotective Agents / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D048448:Phenylcarbamates / Q000737:chemistry / Q000494:pharmacology / Q000627:therapeutic use*; D011237:Predictive Value of Tests; D016032:Randomized Controlled Trials as Topic / Q000379:methods; D000068836:Rivastigmine
chemical_list: D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine